Disulfide Bonds and Cyclic Peptide Chemistry for the Lab

Linear peptides are flexible: in water most short sequences sample a wide range of conformations. Tying the chain into a ring is one of the oldest ways chemists impose order on it. This article covers disulfide bonds and cyclic peptide chemistry from a practical lab perspective: the main types of ring closure, how disulfides are formed and verified, why lactam bridges behave differently, and what cyclization means for storage, buffers and analysis. Two contrasting catalogue examples illustrate the points: a lactam-cyclized melanocortin analog and a linear, helix-forming host-defense peptide.

Why cyclize a peptide?

Cyclization reduces conformational freedom, which can pre-organise a peptide in the shape its target recognises, and it often makes the backbone less accessible to proteases. A review of cyclic peptide therapeutics counted more than 40 cyclic peptide drugs in clinical use, most derived from natural products or peptide hormones, and noted that new cyclic ligands are increasingly designed by rational methods and in-vitro evolution [2]. For a lab user, the relevant consequence is simpler: a cyclic peptide is a different molecule from its linear precursor, with a different mass, retention time and sensitivity to reagents.

The main ring-closing chemistries are:

Linkage	Formed between	Reversible?	Mass change on closure
Disulfide	Two Cys thiols	Yes, by reducing agents	-2.016 Da
Side-chain lactam	Asp/Glu carboxyl + Lys/Orn amine	No (amide)	-18.011 Da
Head-to-tail amide	N-terminal amine + C-terminal carboxyl	No	-18.011 Da
Thioether / other	Various	Generally no	Depends on chemistry

Disulfide bond chemistry

Disulfides are the most common natural cross-link in peptides. A comprehensive review of disulfide-rich peptides describes their roles in folding, stability and receptor recognition, and the synthetic strategies used to install them [1]. The practical essentials:

Formation. After synthesis and cleavage, a peptide with two free cysteines can be oxidised in dilute solution, typically by air oxidation at slightly basic pH, DMSO-assisted oxidation, or iodine. Dilution favours intramolecular ring closure over intermolecular dimers.

Regioselective formation. When a peptide has four or six cysteines, random oxidation can give several disulfide isomers. Chemists solve this with orthogonal cysteine protecting groups (for example Trt removed at cleavage, Acm removed later by iodine), forming one bond at a time [1].

Scrambling and beta-elimination. Disulfides are not inert. At neutral to basic pH, a free thiol can attack an existing disulfide and shuffle the pairing, and under harsher conditions disulfides can undergo beta-elimination to dehydroalanine and persulfide species [3]. A buffer containing a reducing agent, such as DTT or TCEP in a cell-lysis or kinase buffer, will open a disulfide-bridged peptide over time.

Verification. Three complementary checks are standard:

1. Intact mass. The oxidised form is 2.016 Da lighter per disulfide than the reduced form. High-resolution MS resolves this easily; see mass spectrometry identity confirmation.
2. Reduction shift. Treating an aliquot with TCEP and re-analysing should give the +2 Da (per bond) reduced species and, usually, a clear retention-time change.
3. Free-thiol assay or alkylation. Ellman's reagent quantifies free thiols; alkylation with iodoacetamide adds +57.02 Da to each free cysteine, so a fully bridged peptide should show no shift.

Cysteine chemistry overlaps closely with oxidation chemistry, covered in methionine and cysteine oxidation in peptides.

Lactam bridges: the melanocortin example

A side-chain lactam links an acidic residue to a basic one through an ordinary amide bond. Unlike a disulfide it is indifferent to reducing agents and is usually formed on the resin using orthogonally protected Asp/Glu and Lys/Orn side chains.

The classic lactam series comes from alpha-melanotropin (alpha-MSH) research. Al-Obeidi and colleagues designed cyclic analogs of alpha-MSH fragments in which an Asp or Glu at position 5 was bridged to Lys, Orn or shorter diamino acids at position 10, and formed the lactam either in solution or on the solid support [4]. Ring size mattered: in frog and lizard skin bioassays, analogs with a 23-membered ring were the most potent, and enlarging or shrinking the ring reduced activity [4]. Later work in the same scaffold substituted bulky aromatic residues at position 7 and reported receptor-subtype-selective antagonists at cloned melanocortin receptors, showing how a fixed ring can serve as a template for structure-activity studies [5].

Melanotan II belongs to this family: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, a heptapeptide whose Asp and Lys side chains form the lactam, closing a 23-membered ring. From an analytical standpoint:

• The lactam cannot be "opened" by DTT or TCEP, so a reduction test is uninformative; identity rests on intact mass and MS/MS.
• A linear, uncyclized precursor would appear at +18.01 Da relative to the product.
• The ring constrains fragmentation, so MS/MS spectra of cyclic peptides are more complex to interpret than those of linear sequences, because two backbone cleavages are needed to produce a fragment.
• Trp is present, so oxidation products (+16, +32 Da) are the degradants to watch.

A linear contrast: LL-37

Not every structured peptide needs a covalent ring. LL-37, the 37-residue human cathelicidin, contains no cysteine at all. Triple-resonance NMR of isotope-labelled LL-37 in SDS micelles showed a curved amphipathic helix-bend-helix spanning residues 2-31, with the bend between Gly14 and Glu16 and a disordered C-terminal tail [6]. The same study identified KR-12, residues 18-29, as the smallest fragment that retained antibacterial activity in its assays [6].

This matters for the bench because LL-37's structure is environment-dependent rather than locked in. Its conformation in a phosphate buffer, in a detergent micelle and at a lipid membrane can differ, and cationic, amphipathic peptides of this kind are prone to self-association and surface adsorption. Covalent cyclization and environment-induced folding are two different answers to the same flexibility problem, and they call for different handling and characterization.

Handling cyclic and disulfide-containing peptides

• Check buffers for reducing agents before adding a disulfide-bridged peptide, or accept that the reduced form is what you are testing.
• Avoid prolonged storage in solution at basic pH, where thiol-disulfide exchange and beta-elimination accelerate [3].
• Store lyophilized, cold and dry, as for any peptide; see lyophilized peptide storage and stability.
• Read the certificate of analysis for ring-specific evidence: the observed mass should match the cyclic form, not the linear precursor. Per-lot data are on our lab reports page.

Other ways of constraining or protecting a sequence, including D-amino acids, are discussed in D-amino acids and retro-inverso peptides and chemical strategies for peptide stability.

Key takeaways

• Cyclization constrains conformation and changes mass: -2.016 Da per disulfide, -18.011 Da for a lactam or head-to-tail amide.
• Disulfides are reversible and can scramble or be reduced by DTT/TCEP; lactams are stable amides.
• Confirm disulfides by intact mass, a reduction shift and a free-thiol or alkylation test.
• Melanotan II is a lactam-bridged alpha-MSH analog with a 23-membered ring; LL-37 is linear and folds according to its environment.
• Match buffers and storage to the linkage type.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Góngora-Benítez M, Tulla-Puche J, Albericio F. Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chem Rev. 2014;114(2):901-926. PubMed
2. Zorzi A, Deyle K, Heinis C. Cyclic peptide therapeutics: past, present and future. Curr Opin Chem Biol. 2017;38:24-29. PubMed
3. Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
4. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. PubMed
5. Hruby VJ, Lu D, Sharma SD, et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 1995;38(18):3454-3461. PubMed
6. Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem. 2008;283(47):32637-32643. PubMed